pachydermoperiostosis
Conditions
Interventions
Medicine A 200 mg, twice daily, for 1 year
Sponsors
National Center for Child Health and Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)A patient having clinical triad and excluded the following conditions: secondary hypertrophic osteoarthropathy, systemic bone diseases, acromegaly, Graves' disease-associated osteoarthropathy (thyroid acropachy, EMO syndrome) (2)A patient who was found to have gene mutations in the HPGD or SLCO2A1 gene (3)A patient who MR imaging in brain and legs and X-ray photograph in extremities were taken.
Exclusion criteria
Exclusion criteria: Patients who met the following conditions were excluded: (1)allergy to Medicine A, (2)history of asthma, (3)history of gastrointestinal ulcer or bleeding, (4)renal diseases (serum creatinine concentration more than 1.2 mg/dl, including having a history of dialysis), (5)liver dysfunction (serum alanine or aspartate transaminase concentrations more than 3 times the upper limit of normal range), (6)heart failure or myocardial infarction, (7)body weight less than 40 kg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical symptoms and signs | — |
Secondary
| Measure | Time frame |
|---|---|
| serum/urinary PGE2 content | — |
Countries
Japan
Contacts
Public ContactMayumi Sako
National Center for Child Health and Development Division for Clinical Trials
Outcome results
None listed